Related Experiment Video
Updated: Oct 31, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Immunotherapy of High Risk Non-Muscle Invasive Bladder Cancer
Michael Ahdoot1,2, Dan Theodorescu1,2,3
1Department of Surgery (Urology), Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Abstract:
Introduction: Bladder cancer remains a prevalent and often lethal cancer. Fortunately, recent clinical trials using immunotherapeutics demonstrate promise to improve treatment outcomes. Several of these immunotherapies have already established their value in the metastatic space and likely will soon have indications in the non-metastatic space.Areas covered: This review will cover immunotherapies ranging for well-studied BCG administration to more novel medications such as PD-L1/PD-1 inhibitors, CTLA-4 inhibitors, IL-15 super agonists, and immune modulating gene therapies. Specifically, this article will address the mechanisms of actions, clinical evidence supporting their use, and the presence of any FDA regulatory approval for these medications in the treatment of high-risk non-muscle invasive bladder cancer.Expert opinion: With the publication of clinical data supporting the use of immunotherapies, these novel medications are likely to be adopted for treatment of high-grade non-metastatic bladder cancer. While BCG is likely to remain a primary medication for high-grade bladder cancer for the near future, BCG will likely be co-administered with immunomodulatory medications in some patients to enhance the medications effect in the future. Clinical trials are still ongoing and will demonstrate which of these multiple treatment options yield results worthy of a modification in our current treatment paradigm.
Insights
Immunotherapies show promise for treating bladder cancer, including novel agents like PD-L1/PD-1 inhibitors and immune gene therapies. These treatments may soon be approved for non-metastatic bladder cancer, potentially complementing or replacing BCG therapy.
Area of Science:
- Oncology
- Immunology
- Urology
Background:
- Bladder cancer is a significant health concern with high mortality rates.
- Immunotherapeutics are emerging as promising treatments, with established efficacy in metastatic disease.
- Recent advancements suggest potential applications in non-metastatic bladder cancer.
Purpose of the Study:
- To review current and novel immunotherapies for high-risk non-muscle invasive bladder cancer.
- To discuss mechanisms of action, clinical evidence, and FDA approval status.
- To provide expert opinion on the future role of immunotherapy in bladder cancer treatment.
Main Methods:
- Literature review of immunotherapies including BCG, PD-L1/PD-1 inhibitors, CTLA-4 inhibitors, IL-15 super agonists, and gene therapies.
- Analysis of clinical trial data and FDA regulatory approvals.
- Synthesis of expert opinions on treatment paradigms.
Main Results:
- BCG remains a primary treatment, but novel immunotherapies are showing promise.
- PD-L1/PD-1 inhibitors, CTLA-4 inhibitors, IL-15 super agonists, and gene therapies are under investigation.
- FDA approvals are emerging for some immunotherapies in bladder cancer treatment.
Conclusions:
- Immunotherapies are likely to be adopted for high-grade non-metastatic bladder cancer.
- Combination therapies involving BCG and immunomodulatory drugs may enhance treatment effects.
- Ongoing clinical trials will refine the role of these novel agents in the bladder cancer treatment paradigm.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...